Insider Selling: Simulations Plus, Inc. (NASDAQ:SLP) Director Sells 750 Shares of Stock

Simulations Plus, Inc. (NASDAQ:SLP) Director Daniel L. Weiner sold 750 shares of the firm’s stock in a transaction on Friday, September 27th. The shares were sold at an average price of $31.54, for a total transaction of $23,655.00. Following the completion of the transaction, the director now directly owns 6,994 shares of the company’s stock, valued at approximately $220,590.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Simulations Plus Stock Performance

NASDAQ:SLP traded down $0.77 during mid-day trading on Tuesday, reaching $31.25. 183,196 shares of the company’s stock were exchanged, compared to its average volume of 123,044. The firm has a market capitalization of $625.31 million, a PE ratio of 65.19 and a beta of 0.70. Simulations Plus, Inc. has a one year low of $30.22 and a one year high of $51.22. The business’s fifty day simple moving average is $35.56 and its two-hundred day simple moving average is $42.09.

Simulations Plus (NASDAQ:SLP) last announced its earnings results on Tuesday, July 2nd. The technology company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.15 by $0.04. The company had revenue of $18.54 million for the quarter, compared to analysts’ expectations of $17.92 million. Simulations Plus had a net margin of 14.36% and a return on equity of 7.80%. The business’s revenue for the quarter was up 14.2% on a year-over-year basis. During the same period last year, the firm earned $0.20 earnings per share. As a group, equities research analysts forecast that Simulations Plus, Inc. will post 0.51 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. JMP Securities initiated coverage on Simulations Plus in a research report on Tuesday, July 16th. They set a “market perform” rating for the company. William Blair reissued an “outperform” rating on shares of Simulations Plus in a research note on Thursday, September 12th. Craig Hallum reaffirmed a “buy” rating and set a $56.00 price target on shares of Simulations Plus in a research report on Wednesday, July 3rd. KeyCorp assumed coverage on shares of Simulations Plus in a research report on Monday, July 29th. They issued an “overweight” rating and a $47.00 price objective for the company. Finally, Oppenheimer upped their target price on shares of Simulations Plus from $55.00 to $65.00 and gave the company an “outperform” rating in a report on Thursday, June 13th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $56.00.

Hedge Funds Weigh In On Simulations Plus

A number of hedge funds have recently added to or reduced their stakes in SLP. EntryPoint Capital LLC acquired a new stake in shares of Simulations Plus during the 1st quarter worth approximately $57,000. Allspring Global Investments Holdings LLC bought a new position in shares of Simulations Plus in the 1st quarter valued at $70,000. Connecticut Wealth Management LLC acquired a new position in shares of Simulations Plus during the 1st quarter worth $204,000. Los Angeles Capital Management LLC bought a new stake in shares of Simulations Plus during the 2nd quarter worth $206,000. Finally, Janney Montgomery Scott LLC bought a new stake in shares of Simulations Plus during the 1st quarter worth $208,000. Institutional investors own 78.08% of the company’s stock.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.